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ABSTRACT 
Lafora disease (LD, OMIM 254780) is a fatal rare disorder characterized by epilepsy 
and neurodegeneration. Although in recent years a lot of information has been gained on the 
molecular basis of the neurodegeneration that accompanies LD, the molecular basis of 
epilepsy is poorly understood. Here, we present evidence indicating that the homeostasis of 
glutamate transporter GLT-1 (EAAT2) is compromised in mouse models of LD. Our results 
indicate that primary astrocytes from LD mice have reduced capacity of glutamate transport, 
probably because they present a reduction in the levels of the glutamate transporter at the 
plasma membrane. On the other hand, the overexpression in cellular models of laforin and 
malin, the two proteins related to LD, results in an accumulation of GLT-1 (EAAT2) at the 
plasma membrane and in a severe reduction of the ubiquitination of the transporter. All these 
results suggest that the laforin/malin complex slows down the endocytic recycling of the GLT-
1 (EAAT2) transporter. Since, defects in the function of this transporter lead to excitotoxicity 
and epilepsy, we suggest that the epilepsy that accompanies LD could be due, at least in 
part, to deficiencies in the function of the GLT-1 (EAAT2) transporter. 
 
Highlights: 
- GLT-1 glutamate transporter is reduced at the membrane of astrocytes from LD mice. 
- Glutamate transport is also reduced in primary astrocytes from LD mice. 
- Overexpression of laforin and malin impairs ubiquitination of GLT-1 transporter. 
- The laforin/malin complex impairs the endocytic recycling of the GLT-1 transporter. 
 
Key words: Lafora disease, epilepsy, glutamate transport, ubiquitination, endocytosis, 
protein recycling, EAAT2, GLT-1. 
 
Abbreviations: EAAT2, excitatory amino acid transporter 2; GLT-1, glutamate transporter 1; 
LD, Lafora disease; IHC, immunohistochemistry; IHF, immunohistofluorescence; WGA, 
wheat germ agglutinin. 
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1.- INTRODUCTION 
Lafora progressive myoclonus epilepsy (Lafora disease, LD, OMIM 254780) is a fatal 
rare autosomal recessive neurodegenerative disorder with an onset when the patients are 
around 6 to 19 years of age. It is characterized by generalized multiple types of seizures, 
myoclonus and the accumulation of insoluble polyglucosan inclusions, called Lafora bodies 
(LBs), in the cytoplasm of neurons and other cells in peripheral tissues. As the disease 
progresses, patients present a rapid progressive dementia concomitant with an amplification 
of seizures leading to death within a decade after the first symptoms [1],[2]. Up to now, two 
main causative genes have been identified, EPM2A which encodes the dual specificity 
phosphatase laforin and EPM2B which encodes the E3-ubiquitin ligase malin. Although both 
proteins might have independent functions, it is now well known that laforin and malin form a 
functional complex, explaining why patients with mutations in the genes encoding either 
laforin or malin are neurologically and histologically indistinguishable [3]. It has been recently 
described that laforin and malin participate in several processes, such as glycogen 
biosynthesis [4],[5] or regulation of cellular protein homeostasis (proteostasis) (see [6] for 
review). However, in spite of the advances in the understanding of the molecular basis of LD, 
the mechanisms that lead to epilepsy are poorly known. Only recently it has been suggested 
that inhibitory GABAergic neurons could be affected in LD [7],[8], yielding some preliminary 
insights into how epilepsy develops in LD patients. 
In this work we present evidence indicating that the homeostasis of glutamate 
transporter GLT-1, called EAAT2 (Excitatory AminoAcid Transporter 2) in humans, is 
affected in mouse primary astrocytes lacking either EPM2A or EPM2B genes. Glutamate is 
the main excitatory neurotransmitter in the central nervous system and it is implicated in 
important physiological and pathological processes. It is also well known the importance of 
the homeostasis of this neurotransmitter in a healthy brain: when glutamate is released in the 
synaptic cleft, it must be rapidly taken up by different transporters in order to prevent 
glutamate receptors overstimulation, as this can lead to neuronal injury and death in a 
process known as excitotoxicity [9]. GLT-1 (EAAT2) transporter is responsible of up to 90% 
of glutamate uptake, and it is expressed mainly in perisynaptic astrocytes [10],[11],[12],[13]. 
This transporter is incorporated into the astrocytic plasma membrane by exocytosis in a Ca2+ 
dependent manner [14], and recycled by endocytosis upon PKC activation and Nedd4.2-
mediated ubiquitination [15],[16],[17]. Other groups have also described the sumoylation at 
the C-terminal tail as a mechanism of regulation of EAAT2 localization, since EAAT2 
sumoylation retains the transporter in intracellular compartments [18]. However, the 
mechanisms regulating EAAT2 trafficking are still far from being understood. 
There is an increasing evidence of the importance of EAAT2 dysfunction in different 
neurological disorders. Defects in the clearance of glutamate from the synaptic cleft by 
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EAAT2 appear in a wide variety of neurodegenerative diseases, ranging from Alzheimer’s 
disease [19], to amyotrophic lateral sclerosis (ALS) [20], including epilepsy [21]. Dysfunctions 
in the regulation of the subcellular localization of EAAT2 may conduct to altered glutamate 
uptake and excitotoxicity [13],[22], and this could be responsible for the establishment of 
these and other neurological disorders. Thus, understanding the molecular elements 
participating in the homeostasis of EAAT2 becomes an interesting goal to achieve. In this 
work we present evidence indicating that the subcellular location of GLT-1 (EAAT2) 
transporter is altered in Lafora disease cellular and mouse models and that laforin and malin 
affects the endocytic recycling of this transporter. 
 
2.- MATERIALS AND METHODS 
2.1.- Ethic statement, animal care, mice and husbandry 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the Consejo Superior de 
Investigaciones Cientificas (CSIC, Spain). All mouse procedures were approved by the 
animal committee of the Instituto de Biomedicina de Valencia-CSIC [Permit Number: 
INTRA12 (IBV-4)]. All efforts were made to minimize animal suffering. To eliminate the effect 
of differences in the genetic background of the animals, we backcrossed Epm2a-/- and 
Epm2b-/- mice (with a mixed background 129sv:C57BL/6) previously described [23],[24] with 
control C57BL/6JRccHsd mice obtained from Harlan laboratories (Barcelona, Spain), ten 
times to obtain homozygous Epm2a-/- and Epm2b-/- in a pure background. Mice were 
maintained in the IBV-CSIC facility on a 12/12 light/dark cycle under constant temperature 
(23°C) with food and water provided ad libitum. 
 
2.2.- Mammalian cell cultures 
Human neuroblastoma SH-SY5Y cells [kindly provided by Dr. Domingo Barettino 
(Institute of Biomedicine of Valencia, CSIC, Valencia, Spain)] were grown in Dulbecco’s 
Modified Medium/Nutrient Mixture F-12 (Life Technology, Madrid, Spain) supplemented with 
15% inactivated fetal bovine serum (FBS) (Invitrogen, Madrid, Spain), 1% L-glutamine, 100 
units/ml penicillin and 100 μg/ml streptomycin. Human embryonic kidney (HEK293) cells 
were grown in Dulbecco’s Modified Medium (Lonza, Barcelona, Spain), supplemented with 
10% inactivated FBS, 1% L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. 
Both cell types were grown in a humidified atmosphere at 37°C and 5% CO2. 
 
2.3.- Mouse primary astrocyte cell cultures 
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Mouse primary astrocyte cell cultures from control, Epm2a-/- and Epm2b-/- mice were 
obtained from newborn mice cortices as previously described [25]. Cells were grown in 
Dulbecco’s modified Eagle’s medium (Lonza, Barcelona, Spain) containing 20% of 
inactivated fetal bovine serum (FBS), supplemented with 1% L-glutamine, 1% glucose, 1% 
fungizone, 100 units/ml penicillin and 100 μg/ml streptomycin, in a humidified atmosphere at 
37°C with 5% CO2. After the first week, FBS was reduced to 10%. The purity of astrocytes 
was confirmed by immunofluorescence using anti-GFAP (an astrocyte marker; Sigma-
Aldrich, Madrid, Spain), anti-Neurotrophin 3 (a neuron marker; Chemicon International, 
Madrid, Spain) and anti-Iba-1 (a microglia marker; Wako Chemicals, Richmond, USA). 
 
2.4.- Flow cytometry analyses 
Mouse primary astrocytes and human neuroblastoma SH-SY5Y cells were plated in 
60 mm diameter culture dishes and grown in the corresponding media described above in a 
humidified atmosphere at 37ºC with 5% CO2. Cells were transfected with the indicated 
plasmids and 24 hours after transfection, they were washed twice with cold PBS, incubated 
with anti-EAAT2 antibodies (Santa Cruz Biotechnology, Madrid, Spain) at 4°C for 30 minutes, 
washed twice with cold PBS and incubated with phycoerythrin-conjugated goat anti-mouse 
antibodies (Santa Cruz Biotechnology, Madrid, Spain) for 30 min at 4°C. Cells were washed 
again twice with cold PBS and fixed with 4% paraformaldehyde in PBS for 20 minutes. Cells 
were finally detached with trypsin for 5 minutes at 37°C and suspended. Cell bound 
fluorescence was measured in a BD FACSCanto flow cytometer (BD Biosciences, Madrid, 
Spain) and analyzed by the software provided by the manufacturer. 
 
2.5.- Glutamate uptake 
Mouse primary astrocyte cell cultures from control, Epm2a-/- and Epm2b-/- mice were 
seeded 48h before the assay at a density of 2 x 105 cells/well in a 48 wells plate and grown 
in Dulbecco’s modified Eagle’s medium (Lonza, Barcelona, Spain), supplemented with 100 
units/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 10% of inactivated fetal 
bovine serum (Lonza, Barcelona, Spain) in a humidified atmosphere at 37ºC with 5% CO2. 
Cells were washed twice with PBS at 37ºC and then incubated with L-glutamate [2 Ci/ml L-
[3H]glutamate (PerkinElmer, Madrid Spain)] in PBS at 37ºC for 10 min. Incubations were 
carried out in triplicate. For each assay, parallel determinations were performed in a sodium-
free PBS (NaCl was iso-osmotically substituted by choline chloride). Assays were stopped by 
aspiration followed by two washes with ice-cold PBS or sodium-free PBS respectively. Cells 
were lysed in 0.2 M NaOH and accumulated radioactivity measured in a liquid scintillation 
counter (PerkinElmer Liquid Scintillation Analyzer Tri-Carb 2800TR). Glutamate uptake was 
expressed as the fold change in radioactivity incorporation between cells treated with PBS 
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and cells treated with sodium-free PBS, as sodium is required for the GLT-1 mediated co-
transport of glutamate. Each experiment was repeated at least three times. 
 
2.6.- Immunohistochemistry and immunohistofluorescence analyses. 
Male mice of 12 months of age were sacrificed by cervical dislocation. Brain was 
recovered and the two hemispheres separated, one conserved at -80ºC for processing for 
western blot analyses, and the other hemisphere fixed in 4% paraformaldehyde in phosphate 
buffer saline (PBS) and dehydrated for posterior histological analyses. Dehydrated tissues 
were embedded in paraffin and sectioned at 4 µm. For immunohistochemistry analyses 
(IHC), sections were deparaffined, rehydrated, and warmed at 95°C for 10 min in 10 mM 
citrate buffer for antigen retrieval. Sections were blocked in blocking buffer (1% BSA – 5% 
FBS, in PBS) and incubated overnight at 4°C with primary anti-Nedd4 (Abcam, Cambridge, 
UK) antibody diluted at 1/200 in blocking buffer. After three washes of 10 min in PBS, 
sections were incubated for one hour at room temperature with biotin-conjugated rabbit 
secondary antibody diluted at 1/250 in blocking buffer, washed three times with PBS for 5 
min, incubated with the immunopure ABC kit (Fisher scientific, Madrid, Spain) for 30 min in 
darkness, washed three times in PBS for 5 min and developed using metal enhanced dab 
method (Fisher scientific, Madrid, Spain). IHC sections were finally counterstained with 
haematoxylin (Sigma, Madrid, Spain), dehydrated and mounted in DPX (Merck, Germany). 
Images were acquired with a DM6000 Leica Microscope and analyzed with Image J software 
(NIH, Bethesda, MD). 
 For immunohistofluorescence analyses (IHF), sections were deparaffined, rehydrated, 
blocked with sodium borohydrate (1mg/mL) for 40 minutes to avoid autofluorescence and 
warmed at 95°C for 10 minutes in 10 mM citrate buffer for antigen retrieval. Sections were 
blocked in blocking buffer (1% BSA - 5%-FBS) and incubated overnight at 4°C with anti-
EAAT2 antibody (Santa Cruz Biotechnology, Madrid, Spain), anti-glutamine synthase 
(Sigma, Madrid, Spain) or anti-GFAP (Sigma, Madrid, Spain), as indicated in each case. 
After three washes of 10 minutes in PBS, sections were incubated with Alexa Fluor 488-
conjugated anti-mouse (Invitrogen, Madrid, Spain), Alexa Fluor 594-conjugated anti-rabbit 
(Invitrogen, Madrid, Spain), Texas Red-conjugated anti-mouse (Invitrogen, Madrid, Spain) or 
Alexa Fluor 488-conjugated anti-rabbit (Invitrogen, Madrid, Spain) for 45 minutes at room 
temperature in darkness. After two 10-minutes PBS washes, sections were incubated with 
DAPI 0.2 μg/mL (Sigma, Madrid, Spain) in PBS for ten minutes, washed again three times in 
PBS and mounted using Aqua-Poly/Mount coverslip medium (Polysciences, Inc. Eppelheim, 
Germany). Images were acquired with a Leica TCS SP8 confocal microscope (Leica, 
Wetzlar, Germany) and were processed with ImageJ software (NIH, Bethesda, MD).  
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2.7.- Immunofluorescence analyses 
Mouse primary astrocyte cultures were grown on 12-wells plates containing 
coverslips during 24 hours. Cells were washed twice with cold phosphate saline buffer (PBS) 
at 4°C. Then, they were incubated with anti-EAAT2 antibody (Santa Cruz Biotechnology, 
Madrid, Spain) 30 minutes at 4°C. Cells were then washed twice with cold PBS and 
incubated with TexasRed-conjugated anti-mouse antibodies (Invitrogen, Madrid, Spain) for 
30 minutes at 4°C. Cells were washed again with cold PBS and incubated with Wheat Germ 
Agglutinin (WGA) Alexa Fluor 488 conjugate (Invitrogen, Madrid, Spain) during 20 minutes at 
4°C. After two washes with cold PBS, cells were finally fixed with 4% paraformaldehyde 
(PFA) in PBS for 20 minutes, washed three times in PBS and mounted on slices using Aqua-
Poly/Mount coverslip medium (Polysciences, Inc. Eppelheim, Germany). Images were 
acquired with a Leica TCS SP8 confocal microscope (Leica, Wetzlar, Germany) and were 
processed with ImageJ software (NIH, Bethesda, MD). 
 
2.8.- Plasmids 
pCMV-6xHis-ubiquitin, pHA-malin, pFlag-malin, pHA-laforin and pFlag-laforin 
plasmids have been previously described [26]. pCMV-HA-Nedd4.2 plasmid was from Dr. 
Lynne Yenush (Instituto de Biologia Molecular y Celular de Plantas, CSIC, Valencia, Spain). 
pcDNA3-EAAT2 plasmid was a generous gift from Dr. Peter Dodd (School of Chemistry and 
Molecular Biosciences, University of Queensland, Queensland, Australia).  
 
2.9.- Western blot analyses 
Mouse brain homogenates were lysed in RIPA buffer [20 mM Tris-HCl, pH 7.5; 150 
mM NaCl; 1 mM EDTA; 1% NP-40; 1 mM Na3VO4 and complete protease inhibitor cocktail 
(Roche Diagnostics, Barcelona, Spain)] for 20 min at 4°C and centrifuged at 10,000 g for 15 
min. Cell culture extracts were prepared using lysis buffer [25 mMTrisHCl pH 7.4, 15 mM 
EDTA, 50 mM NaF, 0.6 M sucrose, 15 mM Na4P2O7, 1% nonidet P40, 10 mM NaCl, 1 mM 
PMSF, and a complete protease inhibitor mixture (Roche Diagnostics, Barcelona, Spain)]. 
Cells were lysed by repeated passage through 24Gx5/8’’ needle and whole lysates were 
centrifuged at 10,000 x g for 15 min. Supernatants were collected and 30 µg of total protein 
subjected to SDS-PAGE, transferred into nitrocellulose blotting membranes (GE Healthcare 
Life Sciences, Barcelona, Spain) and incubated with the appropriated antibodies: anti-EAAT2 
from Santa Cruz Biotech (Barcelona, Spain); anti-Nedd4.2 and anti-Nedd4 from Abcam 
(Cambridge, UK), anti-actin, anti-HA and anti-Flag (Sigma, Madrid, Spain). After that, they 
were revealed using goat anti-mouse IRDye 680LT (LI-COR Biosciences, Germany) or goat 
anti-rabbit IRDye 800CW (LI-COR Biosciences, Germany) and images obtained with the 
8 
 
Odyssey Infrared Imaging System (LI-COR Biosciences, Germany). The results were 
analyzed using the software Image Studio Lite version 3.1 (LI-COR Biosciences, Germany). 
 
2.10.- Analysis of ubiquitination 
HEK293 cells were co-transfected with plasmids pcDNA3-EAAT2, pCMV-6xHis-
ubiquitin and, when indicated, with pFlag-malin and pFlag-laforin, or pCMV-HA-Nedd4.2, 
using X-treme GENE transfection reagent, according to the manufacturer’s instructions 
(Roche Diagnostics, Barcelona, Spain). After 18 h of transfection, cells were lysed in 
guanidinium hydrochloride to inhibit the action of deubiquitinases and ubiquitinated proteins 
purified by metal affinity chromatography as in [27]. Bound proteins and clarified extracts 
were analyzed by immunoblotting with the appropriate antibodies. 
 
2.11.- Nedd4-2 and Nedd4 degradation assay 
HEK293 cells were transfected with pFlag-laforin and pFlag-malin plasmids using X-
treme GENE transfection reagent (Roche Diagnostics, Barcelona, Spain). 24 hours after 
transfection, 350 μM cycloheximide (Sigma, Madrid, Spain) was added to stop protein 
synthesis. At the indicated times (0 to 24 hours), cells were removed and lysed to analyze 
the amount of endogenous Nedd4-2 and Nedd4 relative to actin by SDS-PAGE and Western 
blot. 
 
2.12.- qRT-PCR analyses 
Dissected brain biopsies or primary astrocyte cultures were frozen in liquid nitrogen 
and stored at –80°C. Thawed samples were homogenized in 2 ml TRIPURE reagent (Roche 
Diagnostics, Manheim, Germany) and total RNA was isolated according to the 
manufacturer's instructions. The concentration of the total RNA was determined using 
Thermo NanoDrop 2000 (Thermo Fisher Scientific inc., Waltham, USA). First strand cDNA 
was synthesized from 1 µg of total RNA using random hexamer and expand reverse 
transcriptase (Roche Diagnostics, Manheim, Germany). cDNA was used as a template for 
real-time PCR. PCR primers and fluorogenic TaqMan probe sets for each gene were 
designed using Universal probe library Service (Roche Molecular Biochemicals) to meet all 
TaqMan design guidelines (Universal probe #103 and suggested primers for SLC1A2 gene). 
Each PCR was carried out in a final volume of 25 l of PCR Master Mix (Applied 
Biosystems), containing 200 nM of each primer and 40 nM of specific fluorescent probe. The 
cycle conditions were 20 s at 95°C for initial denaturing, followed by 35 cycles of 95°C for 3 s 
and 60°C for 30 s in the 7500 Fast Real-time PCR system (Applied biosystems). GAPDH 
was used as an internal standard. Each reaction was done in triplicate from at least three 
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independent experiments. The relative amount of each mRNA was calculated using the 
second derivative comparative Ct method.  
 
2.13.- Statistical analysis 
Data are expressed as means with standard deviation. Statistical significance of 
differences between the groups was evaluated by a paired Student’s t-test with two-tailed 
distribution or by an ANOVA test in case of having more groups. The significance has been 
considered at * p < 0.05, ** p < 0.01, *** p < 0.001, as indicated in each case. 
 
3.- RESULTS 
3.1.- LD mice present a marked reactive astrogliosis in different brain areas. 
We have recently described that Epm2b-/- mice present a clear reactive astrogliosis 
in different areas of the hippocampus [28]. These results were in agreement with previous 
reports [29]. In order to check whether reactive astrogliosis was also present in Epm2a-/- 
mice we carried out an immunohistofluorescence analysis of hippocampal regions of both 
Epm2a-/- and Epm2b-/- mice of 12 months of age and compared them with healthy control 
animals. As shown in Fig. 1, both Epm2a-/- and Epm2b-/- mice presented an increased 
GFAP (Glial Fibrillary Acidic Protein) related staining, a recognized marker of reactive 
astrogliosis, in comparison with control animals. However, we observed no differences in the 
staining when we used anti-glutamine synthase (GS) antibodies (a general astrocyte marker) 
in the assay. Thus, we conclude that although there is no evident change in the number of 
total astrocytes in the studied sections, there is an increase in the number of astrocytes that 
have become reactive in Epm2a-/- and Epm2b-/- mouse brains. Similar results were 
obtained in the cortex and other brain sections (not shown). Therefore, both Epm2a-/- and 
Epm2b-/- mice present reactive astrogliosis in different brain areas. 
 
3.2.- Astrocytes from LD mice present decreased levels of GLT-1 at the plasma 
membrane. 
Since reactive astrogliosis may change the physiological properties of affected 
astrocytes, and since one of the hallmarks of Lafora disease is epilepsy, we planned to study 
the functionality of different astrocytic channels and/or transporters related to 
epileptogenesis. We started the analysis with GLT-1 (EAAT2 in humans) glutamate 
transporter, since it is responsible of up to 90% of glutamate uptake [10],[11],[12],[13]. We 
analyzed the expression of the SLC1A2 gene encoding GLT-1 transporter and the total 
protein levels of this protein in different areas of the brain (hippocampus and cortex) of 12 
month old mice by qRT-PCR, Western blotting and immunohistofluorescence. However, we 
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found no statistical differences between control and Epm2a-/- or Epm2b-/- mice 
(Supplementary Fig. S1), suggesting that expression of GLT-1 is not affected in the brain of 
old LD mice is spite of the reactive astrogliosis present (Fig. 1). 
Then, we analyzed the ability of primary astrocytes to transport glutamate and found 
that astrocytes from both Epm2a-/- and Epm2b-/- mice had lower capacity of glutamate 
uptake in comparison to primary astrocytes from control mice (Fig. 2). These results 
suggested that astrocytes from LD mice have reduced capacity for glutamate transport. We 
analyzed next whether there were differences in the levels of GLT-1 transporter, but again 
we found similar levels both at the level of the expression of corresponding SLC1A2 gene 
(Fig. 3A) and total protein (Fig. 3B) in the primary astrocytes from LD mice in comparison to 
healthy animals. Since GLT-1 is a protein mainly located at the plasma membrane of the 
astrocytes, being its localization regulated by ubiquitin-dependent endocytosis 
[15],[16],[17],[30], we decided to study whether the localization of this transporter was 
affected in primary astrocytes from LD mouse models. With this aim, we stained them with 
anti-EAAT2 antibodies and analyzed them by flow cytometry under native conditions, to label 
only the protein that was present at the outer surface of the plasma membrane. As observed 
in Fig. 3C, the relative fluorescence at the membrane surface was diminished in primary 
astrocytes from Epm2a-/- and Epm2b-/- mice respect to control mice, with a mean reduction 
of around 80% in the case of Epm2a-/- and around 64% in the case of Epm2b-/- mice. 
Primary astrocytes were also analyzed by immunofluorescence using anti-EAAT2 antibodies 
and wheat germ agglutinin (WGA, a plasma membrane marker) under native conditions. As 
observed in Fig. 3D, astrocytes from control mice presented a GLT-1-related fluorescence at 
the outer surface of the plasma membrane that co-localized with the wheat germ agglutinin 
marker. However, we observed a clear decrease in the fluorescence associated to GLT-1 
protein in the case of the astrocytes from Epm2a-/- and Epm2b-/- in comparison to control 
mice. All these results indicate that astrocytes from LD mice present a decrease in the levels 
of GLT-1 at the plasma membrane and that this decrease is not due to altered total GLT-1 
protein levels. 
 
3.3.- Overexpression of laforin and malin increases the levels of EAAT2 at the plasma 
membrane. 
Since the absence of laforin or malin produced a decrease in the levels of GLT-1 at 
the plasma membrane in the astrocytes from LD mice, we decided to study the effect of the 
overexpression of laforin and malin on the subcellular localization of EAAT2, the human 
version of mouse GLT-1. In these studies we used human neuroblastoma SH-SY5Y cells, as 
they retain the ability to express endogenous EAAT2 transporter. SH-SY5Y cells were 
transfected with plasmids expressing laforin and malin and the levels of endogenous EAAT2 
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analyzed by different techniques. First, we confirmed by Western blotting that laforin and 
malin were overexpressed in SH-SY5Y cells (Fig. 4A) and observed that this overexpression 
did not alter the total levels of endogenous EAAT2 present in the cells (Fig. 4A). Second, we 
labelled with anti-EAAT2 antibodies the transfected cells and analyzed them by flow 
cytometry under native conditions, to label only the proteins that were present at the outer 
surface of the plasma membrane. As shown in Fig. 4B, SH-SY5Y cells expressing laforin and 
malin showed an increase in the fluorescence associated to EAAT2 at the surface of the 
plasma membrane (around 3.5 fold increase) respect to cells transfected with empty 
plasmids (mock cells). Taking together, all these results indicate that the overexpression of 
laforin and malin increases the levels of EAAT2 at the plasma membrane, without affecting 
the total cellular level of the protein. 
 
3.4.- Overexpression of laforin and malin prevents the ubiquitination of EAAT2. 
The fact that the levels of GLT-1 (EAAT2) at the plasma membrane were changing 
depending on the presence or not of laforin and malin suggested a possible involvement of 
these proteins on the trafficking/recycling of the GLT-1 (EAAT2) transporter. As indicated 
above, the plasma membrane localization of mouse GLT-1 transporter is regulated by 
ubiquitin-dependent endocytosis [15],[16],[17],[30]. Since laforin and malin form a functional 
complex in which laforin recruits specific substrates to be ubiquitinated by the E3-ubiquitin 
ligase activity of malin, we studied whether the overexpression of laforin and malin affected 
the ubiquitination status of GLT-1 (EAAT2) transporter. To carry out these experiments we 
used human embryonic kidney (HEK293) cells transfected with a plasmid expressing human 
EAAT2 (since the endogenous levels of this transporter are quite low in these cells), a 
plasmid expressing a modified form of ubiquitin with an N-terminal tag of 6xHis (to allow the 
purification of ubiquitinated proteins) and plasmids encoding laforin and malin. Twenty-four 
hours after transfection cells were lysed in guanidinium hydrochloride (to preserve 
ubiquitination of proteins by inhibiting the action of deubiquitinating enzymes) and 
ubiquitinated proteins recovered by metal affinity chromatography. Purified proteins were 
analyzed by Western blotting using anti-EAAT2 antibodies. As shown in Fig. 5, under regular 
conditions EAAT2 showed a clear pattern of ubiquitination (lane 2) that did not change when 
laforin alone was expressed (lane 3). However, when laforin and malin were expressed 
together, we observed a dramatic decrease in the recovery of ubiquitinated forms of EAAT2 
(lane 5). This decrease was also observed in cells expressing malin alone (lane 4), probably 
because HEK293 cells contained enough endogenous laforin to allow malin to form the 
functional complex. These results indicated that, first, EAAT2 was not a direct ubiquitination 
substrate of the laforin/malin complex and second, that the regular ubiquitination of EAAT2 
was prevented by the action of the laforin/malin complex. Since cells overexpressing laforin 
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and malin contained higher levels of EAAT2 at the plasma membrane (Fig. 4; see above), 
the decrease in the ubiquitination status of EAAT2 by the overexpression of laforin and malin 
could be the reason why the transporter gets accumulated at the plasma membrane, due 
probably to an endocytic recycling failure of the transporter. 
It has been described that the E3-ubiquitin ligase Nedd4.2 participates in the 
ubiquitination of EAAT2, regulating cell surface turnover of the transporter [16],[17]. We 
overexpressed Nedd4.2 in HEK293 cells in order to improve the ubiquitination of EAAT2, but 
we did not observe major differences respect to cells transfected with an empty plasmid (Fig. 
5, compare lanes 3 and 6), probably because HEK293 cells may have enough endogenous 
Nedd4.2 protein to allow a maximal ubiquitination. However, in cells co-expressing Nedd4.2 
and the laforin/malin complex we did not recover ubiquitinated forms of EAAT2 (Fig. 5, lane 
7), indicating that the laforin/malin complex either inactivated Nedd4.2 and other alternative 
E3-ubiquitin ligases responsible for the modification of EAAT2, or affected alternative adaptor 
proteins that linked the action of these E3-ubiquitin ligases to EAAT2. 
In order to explore whether Nedd4.2 could be a direct substrate of the laforin/malin 
complex, we analyzed if this complex could ubiquitinate this protein. However, when we 
performed these ubiquitination experiments in HEK293 cells we observed that although 
laforin and malin auto-ubiquitinated themselves (indicating that the complex was active), we 
did not observe any laforin/malin mediated ubiquitination of Nedd4.2, either when 
overexpressed as a fusion protein (HA-Nedd4.2) or when the endogenous levels of Nedd4.2 
were analyzed in the same way (Supplementary Fig. S2A). We extended our analysis to 
Nedd4, the closest functional homologue of Nedd4.2, with similar negative results 
(Supplementary Fig. S2A). Next we studied whether laforin and malin could indirectly affect 
the half-life of Nedd4.2 or Nedd4. HEK293 cells were transfected with plasmids expressing 
laforin and malin, and then treated with cycloheximide to inhibit protein synthesis. As shown 
in Supplementary Fig. S2B, the presence of the laforin/malin complex did not affect 
significantly the half-life of endogenous Nedd4.2 and Nedd4 proteins present in HEK293 
cells.  
However, when we analyzed by immunohistochemistry different regions of the 
hippocampus of Epm2a-/-, Epm2b-/- and control mice of 12 months of age using specific 
anti-Nedd4 antibodies, we observed an increased staining in the samples corresponding to 
LD mice respect to similar sections from control animals (Fig. 6A) (we repeated the same 
experiment with anti-Nedd4.2 antibodies but they were not adequate for IHC techniques). 
Nevertheless, when we analyzed by Western blotting the levels of endogenous Nedd4.2 and 
Nedd4 in brain extracts from control and LD mice, we did not observe major differences (Fig. 
6B). These results could suggest a putative negative correlation between the laforin/malin 
complex and the levels of Nedd4 in some particular neural cells. Alternatively, the 
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laforin/malin complex might affect indirectly the subcellular localization of the GLT-1 (EAAT2) 
transporter by regulating other components of the EAAT2 ubiquitination reaction (i.e., E3-
ubiquitin ligase adaptors). 
 
4.- DISCUSSION 
In recent years, several works have been published explaining part of the molecular 
basis of the dysfunctions present in Lafora disease (LD) (see [6],[31],[32] for review). 
However, we have poor information about the molecular determinants that are responsible 
for the epilepsy that accompanies the disease. In this work we present evidence indicating 
that the homeostasis of the GLT-1 (EAAT2) transporter is compromised in mouse models of 
LD. GLT-1 (EAAT2) is a protein mainly located at the plasma membrane of the astrocytes, 
being its localization regulated by ubiquitin-dependent endocytosis [15],[16],[17],[30]. Our 
results indicate that although the total protein levels of this transporter do not change in 
primary astrocytes from LD mouse models in comparison to astrocytes from control mice, the 
presence of GLT-1 (EAAT2) at the plasma membrane is reduced in primary astrocytes from 
LD mice. We also show that primary astrocytes from these mice have reduced capacity of 
glutamate transport, what is consistent with the reduced levels of the GLT-1 transporter in 
their plasma membrane. On the other hand, the overexpression of laforin and malin results in 
a severe reduction of ubiquitination of EAAT2 and a consequent accumulation of the 
transporter at the plasma membrane. Taking all these results together we suggest that the 
laforin/malin complex affects the endocytic recycling of the GLT-1 (EAAT2) transporter. 
 It is known that GLT-1 (EAAT2) is constitutively endocytosed into the recycling 
endosome via a clathrin-dependent pathway, a process that is dependent on the 
ubiquitination of the C-terminal domain of the transporter by the E3-ubiquitin ligase Nedd4.2 
[16],[17]. Since the laforin/malin complex reduces the ubiquitination of EAAT2, even in cells 
overexpressing Nedd4.2, one possibility is that the complex affects the activity of Nedd4.2. In 
this sense, although we found that the laforin/malin complex did not ubiquitinate Nedd4.2 or 
its closest functional homologue Nedd4, we observed that in the absence of laforin or malin, 
Nedd4 was accumulated in specific neural cells of the hippocampus of LD mice. Therefore it 
seems that there is a negative correlation between the laforin/malin complex and the levels 
of Nedd4 in these cells. 
Another possibility is that the laforin/malin complex could affect the endocytic 
recycling of GLT-1 (EAAT2) transporter by an indirect mechanism. It has been described that 
ubiquitination of substrates by Nedd4.2 is mediated by the binding of the E3-ubiquitin ligase 
to PPXY structural motifs present in its corresponding substrates [33],[34]. In substrates that 
do not contain a PPXY motif, Nedd4.2 binds to specific adaptors that bridge the binding of 
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the E3-ubiquitin ligase to the substrate [35],[36],[37]. Since GLT-1 (EAAT2) transporter does 
not bear PPXY structural motifs [38], this implies the need for intermediate proteins to 
mediate the interaction of Nedd4.2 with GLT-1 (EAAT2). Perhaps the laforin/malin complex 
could affect the stability/activity of the intermediate adaptor, affecting in this way the overall 
functionality of the Nedd4.2-adaptor system.  
In any case our results indicate that primary astrocytes from LD mice have lower 
ability for glutamate transport, probably because they have reduced levels of GLT-1 at the 
plasma membrane. Since defects in the function of this transporter lead to excitotoxicity and 
epilepsy [13],[21],[22], we suggest that the neuronal death and epilepsy that accompanies LD 
could be due, at least in part, to deficiencies in the function of the GLT-1 (EAAT2) 
transporter. Therefore, EAAT2 could be a good target to develop a treatment for epilepsy in 
LD. 
Furthermore, defects in glutamate uptake could also contribute to other alterations 
observed in LD patients. The entry of glutamate mediated by EAAT2 transporter is essential 
to maintain high levels of intracellular glutamate to allow the uptake of cystine into the cells 
by the cystine/glutamate antiporter. As cystine is a precursor of the synthesis of glutathione, 
then glutamate uptake is essential for the synthesis of this metabolite, which plays an 
important role in redox detoxification [39]. For this reason, impairment of glutamate uptake 
could slow the synthesis of glutathione and favor oxidative damage in LD, what would be in 
agreement with the conditions of increased oxidative stress that have been recently 
described in this disease [40]. 
 
5.- CONCLUSIONS 
 In this work we present evidence indicating that glutamate transport is impaired in 
primary astrocytes from LD mice. This is probably due to altered homeostasis of the 
glutamate transporter GLT-1 (EAAT2) at the plasma membrane. Since defects in the function 
of this transporter lead to excitotoxicity and epilepsy, we suggest that the epilepsy that 
accompanies LD could be due, at least in part, to deficiencies in the function of the GLT-1 
(EAAT2) transporter. 
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FIGURE LEGENDS 
Figure 1: GFAP expression is increased in LD mice, indicating reactive astrogliosis. 
Hippocampal regions from 12 months old control, Epm2a-/- and Epm2b-/- mice were 
analyzed by immunohistofluorescence using anti-glutamine synthase (GS, in green, upper 
panels) and anti-GFAP (in red, middle panels) as primary antibodies and Alexa Fluor-488 
conjugated anti-rabbit ant Texas red-conjugated anti-mouse as secondary antibodies. A 
merged analysis of both fluorescences is presented in the lower panels. A representative 
picture of the analysis of samples from three different mice of each type is presented. White 
bar: 50 μm. 
 
Figure 2: Glutamate uptake is impaired in primary astrocytes from LD mice. Glutamate 
uptake was carried out as described in Materials and Methods. As GLT-1 co-transports 
glutamate and Na+, results are expressed as the ratio between the glutamate uptake in a 
buffer containing Na+ and the glutamate uptake in an osmotically-equivalent buffer lacking 
Na+. Values are the mean of 5 different experiments (bars indicate standard deviation, 
asterisks denote significant differences comparing the corresponding groups with values 
from control astrocytes; ***p<0.001 using ANOVA test). 
 
Figure 3: Levels of GLT-1 transporter are decreased at the plasma membrane of primary 
astrocytes from LD mice. A) qRT-PCR analysis of the expression of SLC1A2 gene encoding 
the GLT-1 glutamate transporter. qRT-PCR was performed in at least three independent 
samples of primary astrocytes from control and LD mice, as described in Materials and 
Methods; bars indicate standard deviation. B) Western blot analyses of the total levels of 
GLT-1 in primary astrocytes. Crude extracts (30 g) from primary astrocytes from control and 
LD mice were prepared and analyzed by immunoblotting using anti-EAAT2 and anti-actin 
(loading control) antibodies. No differences were observed in the total amount of GLT-1 in 
the different samples. C) Analysis of the levels of GLT-1/EAAT2 transporter at the plasma 
membrane by flow cytometry. Primary astrocytes from control and LD mice were analyzed 
under native conditions by flow cytometry, as described in Materials and Methods, using 
mouse anti-EAAT2 and phycoerythrin-conjugated goat anti-mouse antibodies. Graphics 
represent the levels of phycoerythrin (PE)-dependent fluorescence respect to the number of 
cells (count); the vertical line separates the PE-dependent fluorescence (P9) from unspecific 
cellular signals (this threshold was determined using cells without anti-EAAT2 antibody). PE-
dependent fluorescence levels in the samples were referred to the levels found in the primary 
astrocytes from control mice (100%). Flow cytometry analyses were repeated three times 
and the mean relative fluorescence of each type of primary astrocytes is indicated in the 
bottom panel (bars indicate standard deviation, asterisks denote significant differences 
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comparing the corresponding groups with values from control astrocytes; ***p<0.001 using 
ANOVA test). D) Similar samples of these cells were also analyzed by immunofluorescence 
using anti-EAAT2 antibodies and Wheat Germ Agglutinin (WGA) Alexa Fluor 488 conjugate 
(to mark plasma membrane). Fluorescence of the two markers was merged to demonstrate 
the co-localization of the signals. 
 
Figure 4: Protein levels of EAAT2 at the plasma membrane are increased in cells 
overexpressing laforin and malin. A) Human neuroblastoma SH-SY5Y cells were transfected 
with plasmids expressing Flag-laforin and Flag-malin. Crude extracts (30 g) were prepared 
and the total levels of endogenous EAAT2 and actin analyzed by Western blotting. Similar 
crude extracts were also analyzed to demonstrate the overexpression of laforin and malin 
(anti-Flag antibody). B) SH-SY5Y cells transfected with plasmids expressing laforin and 
malin or with empty plasmids (mock cells) were analyzed under native conditions by flow 
cytometry, as described in Materials and Methods, using mouse anti-EAAT2 and 
phycoerythrin-conjugated goat anti-mouse antibodies. Graphics represent the levels of 
phycoerythrin (PE)-dependent fluorescence respect to the number of cells (count); the 
vertical line separates the PE-dependent fluorescence (P2) from unspecific cellular signals 
(this threshold was determined using cells without anti-EAAT2 antibody). PE-dependent 
fluorescence levels in the samples were referred to the levels found in the mock cells (1x). 
Flow cytometry analyses were repeated three times and the mean relative fluorescence 
indicated (lower panel; bar indicate standard deviation, asterisks denote significant 
differences comparing the corresponding groups; *p<0.05 using a paired Student’s t-test). 
 
Figure 5: Ubiquitination of EAAT2 is decreased in cells overexpressing laforin and malin. 
HEK293 cells were transfected with the indicated plasmids. Ubiquitinated proteins were 
recovered by metal-affinity chromatography as indicated in Materials and Methods. Proteins 
bound to the metal-affinity column were analyzed by Western blotting using anti-EAAT2 
antibodies. Crude extracts (CE, 30 g) were also analyzed by Western blotting using the 
indicated antibodies: anti-EAAT2, anti-Flag (to detect Flag-laforin and Flag-malin), anti-HA 
(to detect HA-Nedd4.2) and anti-actin. The fuzzy bands in the CE are probably due to the 
presence of 6 M guanidinium hydrochoride in the extracts. Ubiquitinated forms of EAAT2 are 
indicated. 
 
Figure 6: Hippocampal regions of LD mice show higher levels of Nedd4. A) 
Hippocampal regions (cornus ammonis 1; CA1) from control, Epm2a-/- and Epm2b-/- mice of 
12 months of age were analyzed by immunohistochemistry using anti-Nedd4 antibodies, as 
indicated in Materials and Methods. A representative picture of the analysis of samples from 
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three different mice of each type is presented. B) Brain crude extracts (30 g) from control 
and LD mice of 12 months of age were analyzed by Western blotting using anti-Nedd4, anti-
Nedd4.2 and anti-actin antibodies. 
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